Annamycin anthracycline analog data

ARNX announced preliminary results of its Phase I dose-escalating safety trial of Annamycin in 30 patients

Read the full 166 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE